IP Library › Granted Patent US 10,024,868
Granted Patent B2
US 10,024,868 · App. 13/377,091 · Granted Jul 17, 2018

Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy

Inventors: Kostantinos (Kostas) Kosmatopoulos (Paris, FR); Jeanne Menez-Jamet (Montrouge, FR)
Assignee: Vaxon Biotech
G01N33/6878C07K7/06C07K14/4748G05D16/20G11C13/02C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,024,868
App. No.
13/377,091
Granted
Jul 17, 2018
Kind
B2
Abstract

The present invention provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype, based on peptides representing shared epitopes of tumor antigens. In particular, the invention relates to a method for identifying a HLA-B*0702-restricted peptide which can trigger a cytotoxic response against several antigens from one single multigenic family, and to several such epitopes.

Claims (11)

1. An isolated peptide consisting of a HLA-B*0702-restricted epitope selected from the group consisting of SEQ ID NO:52 to 54.

2. A chimeric polypeptide, comprising two or more HLA-B*0702-restricted epitopes selected from the group consisting of SEQ ID NO:32-67.

3. A composition comprising at least, as an active ingredient, the isolated peptide according to claim 1 , or the chimeric polypeptide according to claim 2 , and further comprising a pharmaceutical carrier.

4. A kit of parts comprising, in separate containers:

(i) a first peptide comprising a HLA-B*0702-restricted epitope, wherein said first peptide is a chimeric polypeptide comprising two or more HLA-B*0702-restricted epitopes selected from the group consisting of SEQ ID NO: 2 to 31, and

(ii) a second peptide consisting of the chimeric polypeptide of claim 2 .

5. The kit according to claim 4 , wherein said first peptide comprises a sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, and said second peptide comprises the sequence of SEQ ID NO: 54.

6. The kit according to claim 4 , which is a vaccination kit, wherein said first and second peptides are in separate vaccination doses.

7. The isolated peptide according claim 1 , wherein the HLA-B*0702-restricted epitope consists of the sequence of SEQ ID NO: 52.

8. The isolated peptide according claim 1 , wherein the HLA-B*0702-restricted epitope consists of the sequence of SEQ ID NO: 53.

9. The isolated peptide according claim 1 , wherein the HLA-B*0702-restricted epitope consists of the sequence of SEQ ID NO: 54.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2024
From: VAXON BIOTECH
To: KRIPTIC PHARMACEUTICALS LIMITED
Reel/Frame 067492/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2023
From: VAXON BIOTECH
To: KRIPTIC PHARMACEUTICALS LIMITED
Reel/Frame 063449/0437 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2012
From: KOSMATOPOULOS, KOSTANTINOS; MENEZ-JAMET, JEANNE
To: VAXON BIOTECH
Reel/Frame 027782/0346 →
Continuity (1)
Related Publication 20120142894A1 · Jun 7, 2012
Cited By (2)
US 12,290,554 US 12,364,741